Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies
Main finding · FVC improvement >10%Result — go to the resultOdds ratio 3.97 95% CI 1.07–14.75Authors' conclusion
iv CYC showed better functional outcomes than other immunosuppressants in IIM-ILD.
Study context
- Population
- Patients with IIM-ILD from the EPIMAR and Cruces cohorts (81% female; mean age 50.4 years)
- Participants
- 47 patients
- Exposure
- Iv CYC vs other immunosuppressive regimens as induction treatment
- CYCn = 22
- non-CYCn = 25reference
- Outcome
- Improvement >10% in FVC from baseline
- Follow-up
- 6 to 12 months
Methodological detailslogistic regression
- Logistic regression
Main finding
FVC improvement >10%
Odds ratio
3.97
95% CI 1.07–14.75
By group
CYCvs non-CYC
OR 3.97 (95% CI 1.07–14.75)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Methyl-prednisolone pulses received
P = 0.03
Initial GC doses >30 mg/d
P = 0.001
Average prednisone dose · 6 months
P = 0.001
Original publication
Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies. Semin Arthritis Rheum. Published 11 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →